This article was originally published in The Gray Sheet
Office of Compliance Software Expert Stewart Crumpler retires from FDA June 29 after nearly 28 years with the agency. He will join the private sector as assistant-VP for Part 11 program management at American Home Products' Wyeth Ayerst unit. John Murray is expected to fill Crumpler's position at OC...
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.